Health Affairs, 28, no. 1 (2009): w125-w137 (Published online 16 December 2008) doi: 10.1377/hlthaff.28.1.w125 © 2009 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Figures Only Full Text (HTML) Reprint (PDF) Appendices Table Of Contents Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sood, N. Articles by Goldman, D. P. Search for Related Content PubMed PubMed Citation Articles by Sood, N. Articles by Goldman, D. P. Related Collections Health Reform International Issues Pharmaceuticals Chronic Care Health Spending Consumer Issues Related Articles

Web Exclusives

The Effect Of Regulation On Pharmaceutical Revenues: Experience In Nineteen Countries

We describe pharmaceutical regulations in nineteen developed countries from 1992 to 2004 and analyze how different regulations affect pharmaceutical revenues. First, there has been a trend toward increased regulation. Second, most regulations reduce pharmaceutical revenues significantly. Third, since 1994, most countries adopting new regulations already had some regulation in place. We find that incremental regulation of this kind had a smaller impact on costs. However, introducing new regulations in a largely unregulated market, such as the United States, could greatly reduce pharmaceutical revenues. Finally, we show that the cost-reducing effects of price controls increase the longer they remain in place.

                      What's this?

Related Articles

• Darius N. Lakdawalla, Dana P. Goldman, Pierre-Carl Michaud, Neeraj Sood, Robert Lempert, Ze Cong, Han de Vries, and Italo Gutierrez
  U.S. Pharmaceutical Policy In A Global Marketplace
  Health Affairs, January/February 2009; 28(1): w138-w150.
  [Abstract] [Full Text] [Figures Only] [PDF] [Appendix]
   
  
• Murray Aitken, Ernst R. Berndt, and David M. Cutler
  Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point
  Health Affairs, January/February 2009; 28(1): w151-w160.
  [Abstract] [Full Text] [Figures Only] [PDF]
   
  
• F.M. Scherer
  Price Controls And Global Pharmaceutical Progress
  Health Affairs, January/February 2009; 28(1): w161-w164.
  [Abstract] [Full Text] [PDF]
   
  
• Arjun Jayadev and Joseph Stiglitz
  Two Ideas To Increase Innovation And Reduce Pharmaceutical Costs And Prices
  Health Affairs, January/February 2009; 28(1): w165-w168.
  [Abstract] [Full Text] [PDF]
   
  

This article has been cited by other articles:

				D. N. Lakdawalla, D. P. Goldman, P.-C. Michaud, N. Sood, R. Lempert, Z. Cong, H. de Vries, and I. Gutierrez U.S. Pharmaceutical Policy In A Global Marketplace Health Aff., January 1, 2009; 28(1): w138 - w150. [Abstract] [Full Text] [PDF]

				F.M. Scherer Price Controls And Global Pharmaceutical Progress Health Aff., January 1, 2009; 28(1): w161 - w164. [Abstract] [Full Text] [PDF]

				A. Jayadev and J. Stiglitz Two Ideas To Increase Innovation And Reduce Pharmaceutical Costs And Prices Health Aff., January 1, 2009; 28(1): w165 - w168. [Abstract] [Full Text] [PDF]